Please ensure Javascript is enabled for purposes of website accessibility

New Report Shows Promising Coronavirus Vaccine Data

By Morgan McSweeney - Mar 30, 2021 at 6:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Public health experts and average citizens alike have been hoping that vaccines can tackle this one big issue.

As vaccines are rolled out across the U.S., the light at the end of the tunnel of the coronavirus pandemic is getting brighter. Almost 30% of Americans have received at least one dose of a COVID-19 vaccine, but questions about their efficacy in preventing disease and viral transmission remain. Luckily, one recent study from across the world is reporting positive news about Pfizer (PFE -0.70%) and Moderna's (MRNA -0.34%) vaccines' capabilities. 

Here's what new real-world data from Israel tells us about vaccines and transmissibility. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$50.98 (-0.70%) $0.36
Moderna, Inc. Stock Quote
Moderna, Inc.
$141.80 (-0.34%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.